Sanofi snaps up inhaled insulin licence


Pharma major Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialise Mannkind’s recently-approved Afrezza inhaled insulin powder for global distribution.

Sanofi will pay $150 million (£89 million) up front, plus up to $775 million in performance milestones. Mannkind will continue to manufacture the product, but Sanofi will cover regulatory and development activities, including expanding manufacturing capacity.


Related Content

Inhaled insulin approved in US

30 June 2014 Business

news image

European committee recommends approval for generic long-acting insulin

Compulsory licences: necessity or threat?

23 May 2013 Comments

news image

Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?

Most Commented

Snow soaks up pollutants from engine exhausts

14 January 2016 Research

news image

Air quality regulators should consider freezing temperatures and snow

New law on legal highs approved in UK

1 February 2016 News and Analysis

news image

A blanket ban on New Psychoactive Substances has been given final approval and will come into force in April